DOC¸ñʽÂÛÎÄ£¬·½±ãÄúµÄ¸´ÖÆÐÞ¸Äɾ¼õ
¿¹ÈËDcR3µ¥¿Ë¡¿¹ÌåµÄÑÐÖÆ¼°Æä¼ø¶¨
£¨×÷Õß:___________µ¥Î»: ___________Óʱà: ___________£©
×÷ÕߣºÎâ´º·ç, ÂíÖÒÉ, ÍõÐãÀö, Ñî¿¡Áá, ÑîÑó, ÕÅÔ½, ͼÃÇÎÚÁ¦¼ª, ÇÇ¿¡»ª
¡¾ÕªÒª¡¿ Ä¿µÄ: ÖÆ±¸¿¹ÈËDcR3µ¥¿Ë¡¿¹Ì壨mAb£©, ²¢¼ø¶¨ÆäÌØÒìÐÔ¡£·½·¨: ´¿»¯µÄHisDcR3Èںϵ°°×ÃâÒßСÊó, Ó¦ÓÃÁܰÍϸ°ûÔÓ½»Áö¼¼ÊõÖÆ±¸¿¹ÈËDcR3 mAb²¢½øÐд¿»¯, ´¿»¯ºóµÄ¿¹Ìå¾Western blotºÍELISA·½·¨¼ø¶¨ÆäÌØÒìÐÔ¡¢ IgÑÇÐͺÍЧ¼Û¡£½á¹û: »ñµÃ5ÖêÎȶ¨·ÖÃÚ¿¹DcR3 mAbµÄÔÓ½»Áöϸ°û, ¾ùÊôIgG1ÑÇÐÍ, Æä¸¹Ë®¿¹ÌåЧ¼ÛΪ1¡Á10-5¡«1¡Á10-7, Western blotÏÔʾ5Öêϸ°û·ÖÃÚµÄmAb¾ù¿Éʶ±ðDcR3µ°°×, ÆäÖÐ1Ö꣨1B1£©¿ÉÓëSW480ϸ°û³É·Ö·´Ó¦¡£½áÂÛ: ³É¹¦½¨Á¢Îȶ¨·ÖÃÚ¿¹ÈËDcR3 mAbµÄÔÓ½»Áöϸ°ûÖê, Æä·ÖÃڵĿ¹ÌåÌØÒìÐÔÇ¿¡¢ Ч¼Û¸ß, ΪÑо¿DcR3ÔÚ×éÖ¯Öеıí´ï¡¢ ·Ö²¼¼°ÑÐÖÆELISAÊÔ¼ÁºÐµì¶¨»ù´¡¡£ ¡¾¹Ø¼ü´Ê¡¿ DcR3 µ¥¿Ë¡¿¹Ìå ÖÆ±¸
[Abstract] AIM: To prepare monoclonal antibodies(mAbs) against human DcR3 and identify their characterization. METHODS:
DOC¸ñʽÂÛÎÄ£¬·½±ãÄúµÄ¸´ÖÆÐÞ¸Äɾ¼õ
BALB/c mice were immunized with purified HisDcR3 protein, and mAbs against DcR3 which prepared by hybridoma technique were purified and identified by their specificity, subtype, titers via ELISA and Western blot. RESULTS: Five hybridoma cell lines secreting mAbs against human DcR3 were obtained, which were determined as IgG1 subtype and ascites titers of five mAbs against DcR3 reached 1¡Á10-5-1¡Á10-7. Five mAbs were proved to recognize HisDcR3 protein specifically, one of which (1B1) could recognize SW480 cell. CONCLUSION: mAbs against DcR3 with high titers and specificity have been prepared and purified successfully, which laid a foundation for the study of DcR3 expression, distribution in tissu and development of ELISA kit.
[Keywords]DcR3; monoclonal antibody; preparation ÓÕÆÊÜÌå3(decoy receptor 3, DcR3, ÓÖ³ÆTR6)Ϊ½üÄêз¢ÏÖµÄÒ»ÖÖ¿ÉÈÜÐÔÖ×Áö»µËÀÒò×ÓÊÜÌå(TNFR)³¬¼Ò×å³ÉÔ±, ¿É¾ºÕùÐÔ½áºÏÖ×Áö»µËÀÒò×Ó(TNF)³ÉÔ±LIGHT¡¢ FasL¼°TL1A[1, 2], µ«²¢²»½éµ¼Ï¸°ûµòÍö, ÔÚϸ°ûµÄÉú³¤¡¢ ·Ö»¯¡¢ ËÀÍöÒÔ¼°ÃâÒßµ÷½ÚµÈ·½Ãæ·¢»ÓÖØÒª×÷ÓÃ, ÓëÖ×Áö¡¢ ×ÔÉíÃâÒß¼²²¡¡¢ ÒÆÖ²ÅųâµÈÃÜÇÐÏà¹Ø¡£Ó¦ÓÃDcR3¿¹ÌåÑо¿DcR3ÔÚÉÏÊö²¡±ä×éÖ¯»òϸ°ûÖеıí´ïÏÖÒѳÉΪÑо¿Èȵ㡣Ŀǰ, ¹úÍâÒÑÓÐÉÌÆ·»¯µÄ¿¹ÈËDcR3 mAb, µ«¼Û¸ñ°º¹ó, ¹úÄÚÉÐÎÞÕâ·½ÃæµÄÑо¿±¨µÀ¡£ÎÒÃÇÔËÓÃÁܰÍϸ°ûÔÓ½»Áö¼¼ÊõÖÆ±¸ÁË¿¹ÈËDcR3 mAb, ²¢½øÐÐÁ˼ø¶¨, ΪÑо¿DcR3ÔÚ×éÖ¯Öеıí´ï¡¢ ·Ö²¼¼°ÑÐÖÆ
DOC¸ñʽÂÛÎÄ£¬·½±ãÄúµÄ¸´ÖÆÐÞ¸Äɾ¼õ
ELISAÊÔ¼ÁºÐµì¶¨»ù´¡¡£ 1 ²ÄÁϺͷ½·¨
1.1 ²ÄÁÏ ´¿»¯µÄHisDcR3Èںϵ°°×Ϊ±¾ÊÒ×ÔÖÆ[3]; RPMI1640¹º×ÔHyclone¹«Ë¾; PEG4000¹º×ÔMerck¹«Ë¾; HAT¡¢ HT¹º×ÔSigma¹«Ë¾; HRP±ê¼ÇµÄÑò¿¹Êó¼°Ñò¿¹ÍÃIgG¿¹Ì幺×ÔSanta Cruze¹«Ë¾; ¿¹ÌåÑÇÀà²â¶¨ÊÔ¼ÁºÐ¹º×ÔSerotech¹«Ë¾; Protein AÇ׺ͲãÎö½º¹º×ÔPierce¹«Ë¾; PVDFĤ¹º×ÔAmresco¹«Ë¾; ECL»¯Ñ§·¢¹âÊÔ¼ÁºÐ¹º×ÔAmersham¹«Ë¾¡£Sp2/0ϸ°ûÖêÈ¡×Ô¶«±±Ê¦·¶´óѧϸ°ûÒÅ´«Ëù; ¸ß±í´ïDcR3µÄÈ˽᳦°©SW480ϸ°ûÖêÓɱ¾ÊÒ±£´æ; BALB/cСÊó(6¡«8ÖÜÁä, ´ÆÐÔ, Çå½à¼¶)¹º×Ô¼ªÁÖÊ¡ÉúÎïÖÆÆ·Ëù¡£ 1.2 ·½·¨
1.2.1 ¶¯ÎïÃâÒß ´¿»¯µÄHisDcR3Èںϵ°°×ÃâÒßBALB/cСÊó, ³õ´ÎÃâÒßÈ¡100 ¦ÌL (Ô¼50 ¦Ìg)¿¹Ô¼ÓµÈÁ¿¸¥ÊÏÍêÈ«×ô¼Á³ä·ÖÈ黯, ¸¹Ç»×¢Éä, µÚ14ÌìÈ¡100 ¦ÌL(Ô¼50 ¦Ìg)¼ÓµÈÁ¿¸¥Êϲ»ÍêÈ«×ô¼Á¼ÓÇ¿ÃâÒß, ÒÔºóÿ¸ô2ÖܵÈÁ¿¿¹Ô²»¼Ó×ô¼Á¸¹Ç»ÃâÒß2´Î, ²â¶¨Ð¡ÊóѪÇ忹ÌåЧ¼Û´ï1¡Ã106ÒÔÉÏʱ׼±¸ÈÚºÏ, ÈÚºÏǰ3 dȡЧ¼Û×î¸ßµÄСÊó¸¹Ç»×¢É俹Ô100 ¦Ìg¡£
1.2.2 ÔÓ½»Áöϸ°ûÖêµÄ½¨Á¢¼°mAbµÄÖÆ±¸ (1)ϸ°ûÈÚºÏ: ÎÞ¾úÌõ¼þÏÂ, È¡¶ÔÊýÉú³¤µÄSp2/0ϸ°û, 1000 r/minÀëÐÄ8 min, ÆúÉÏÇå, ÓÃRPMI1640²»ÍêÈ«ÅàÑøÒº»ìÐüϸ°ûºó¼ÆÊý, È¡ËùÐèµÄϸ°ûÊý¡£ÖƱ¸ÃâÒßСÊóƢϸ°ûÐüÒº, ½«Sp2/0ϸ°ûÓëÆ¢Ï¸°û°´1¡Ã5µÄ±ÈÀý»ìºÏ, 37¡æË®Ô¡500 mL/L PEG4000×÷ÓÃϽøÐÐÈÚºÏ, ÈںϺó1000 r/min
DOC¸ñʽÂÛÎÄ£¬·½±ãÄúµÄ¸´ÖÆÐÞ¸Äɾ¼õ
ÀëÐÄ8 min, ÆúÉÏÇå, Óú¬ÓÐËÇÑøÏ¸°ûµÄHATÑ¡ÔñÅàÑøÒºÇáÇá»ìÐü, ½ÓÖÖÔÚ96¿×ϸ°ûÅàÑø°åÖÐ, ÖÃ37¡æ¡¢ 50 mL/L CO2ÅàÑøÏäÅàÑø¡£µÚ10Ìì»»HTÑ¡ÔñÅàÑøÒº, µÚ14Ìì»»º¬200 mL/L̥ţѪÇåµÄRPMI1640ÍêÈ«ÅàÑøÒº¡£(2)ɸѡ¼°¿Ë¡»¯: 2¡«3Öܺóµ±ÔÓ½»Áöϸ°û³¤ÖÁ¿×µ×Ãæ»ý1/10ÒÔÉÏʱ, ·Ö±ð°ü±»HisDcR3Èںϵ°°×ÓëHisµ°°×, ͬʱÉèÁ¢Òõ¡¢ ÑôÐÔ¼°¿Õ°×¶ÔÕÕ, Ó¦Óüä½ÓELISA·½·¨¼ì²âÅàÑøÉÏÇåÒº¡£ÒÔP/N¡Ý2.1ΪÑôÐÔ, ѡȡÓëHisDcR3Èںϵ°°×·´Ó¦ÑôÐÔ¶øÓëHisµ°°×·´Ó¦ÒõÐÔ¿×µÄϸ°ûͨ¹ýÓÐÏÞÏ¡ÊÍ·¨Á¬Ðø¿Ë¡2¡«3´Î, Ö±ÖÁËùÓе¥¸ö¿Ë¡ϸ°ûÑôÐÔ¿×ÂÊΪ100%ʱÀ©´óÅàÑø, ½øÐÐϸ°û¶³´æºÍ¸¹Ë®ÖƱ¸¡££¨3£©¸¹Ë®ÖƱ¸¼°´¿»¯:ÿֻBALB/cСÊó¸¹Ç»×¢ÉäÎÞ¾úÒºÌåʯÀ¯500 ¦ÌL, 7 dºóÿֻÊó¸¹Ç»½ÓÖÖÔÓ½»Áöϸ°û6¡Á105¸ö, 14 d×óÓҲɼ¯¸¹Ë®¡£SiO2Îü¸½·¨¶Ô¸¹Ë®½øÐÐÔ¤´¦Àí, ²ÉÓÃÐÁËá±¥ºÍÁòËáï§³Áµí·¨[4]¡¢ProteinAÇ׺ͲãÎö½øÐд¿»¯, ×ÏÍâ·Ö¹â¹â¶È·¨²â¶¨´¿»¯ºómAbº¬Á¿, ´¿»¯ºómAb¹ýÂ˳ý¾ú¼ÓµÈÁ¿¸ÊÓÍ, ·Ö×°-70¡æ¶³´æ¡£ 1.2.3 mAbµÄ¼ø¶¨ £¨1£©Ð§¼ÛµÄ²â¶¨: ½«´¿»¯Ç°ºóµÄmAb±¶±ÈÏ¡ÊÍ, ÒÔ1¡Ã200Ï¡Ê͵ÄÕý³£Ð¡ÊóѪÇå×÷ΪÒõÐÔ¶ÔÕÕ, Ó¦Óüä½ÓELISA·½·¨²â¶¨A492, ÒÔP/N¡Ý2.1ΪÑôÐÔ¡££¨2£©ÃâÒßÇòµ°°×ÀàºÍÑÇÀàµÄ¼ø¶¨: °´²Ù×÷˵Ã÷½«ÔÓ½»ÁöÉÏÇå1¡Ã200Ï¡ÊÍ, È¡150 ¦ÌLÏ¡ÊÍÒº¼ÓÈ뺬ÓÐÑÇÀඨÐÔÊÔ¼ÁµÄÊԹܵײ¿, 30 sºó½«ÊÔÖ½Ìõ²åÈë¹Üµ×, 5¡«10 minºó¹Û²ì½á¹û, ÅжÁÇáÁ´¡¢ ÖØÁ´¡£(3)ÔÓ½»Áöϸ°ûȾɫÌåºËÐÍ·ÖÎö: Éú³¤Á¼ºÃµÄÔÓ½»Áöϸ°ûÐüÒº10 mL¼ÓÈëÇïË®ÏÉËØ, ʹÆäÖÕŨ¶ÈΪ0.1 mg/L, ¼ÌÐøÅàÑø3 h, 1000 r/minÀëÐÄ10 min, ÖØÕôË®ÊÒεÍÉø´¦Àí
Ïà¹ØÍÆ¼ö£º